Biogen

The approval by the US Food and Drug Administration last Thursday of the antibody treatment Leqembi, which significantly slows the progression of Alzheimer's in its early stages, has given hope to millions of patients and their families. 

The drug is the fruit of the collaboration between American biotechnology company Biogen and Japan's Eisai.

One year after the first meeting of the Healthcare & Life Sciences group organized by the Hellenic Federation of Enterprises (SEV) within the framework of the Innovative Greeks initiative, the 5th consecutive Meetup is being organized and will host Dr Stelios Papadopoulos, chairman of the board of the American biotechnology company Biogen.

The US Food and Drug Administration on Jan. 6 approved a highly anticipated new drug designed to slow cognitive decline in patients in mild and early stages of Alzheimer's disease.

The rapid rise of the U.S. dollar since the start of the year is a double-edged sword for American multinational companies, pushing some of them to decide whether to hedge or reposition their activities abroad to avoid fallout.    

For an importer, the surge in the greenback against the euro, yen or British pound is a plus, because it makes the products they buy cheaper.  

Coronavirus vaccines will drastically change our lives for the better, but not overnight, and will provide protection for a long time, according to the consensus among nine Greek scientists working abroad and contacted by Kathimerini.

What the "new normal" for 2021 will be globally, will depend on the number of inoculations over a short period of time, they say.